The most recently added clinical trials across every neurology subspecialty — one feed, updated continuously. Get them weekly by email or via RSS.
Primary effectiveness end point (residual/re-accumulation of hematoma >10 mm at 6 months or surgery on the cSDH within 6 months) occurred in 11.6% (17/146) with MMAE plus SOC vs 22.1% (29/131) with SOC alone — common OR…
View trial →Primary outcome (mRS 0–2 at 90 days) was not met: 337/549 (61.4%) nerinetide vs 329/556 (59.2%) placebo; adjusted RR 1.04 (95% CI 0.96–1.14), p=0.35. In the pre-specified alteplase-stratified subgroup, nerinetide improve…
View trial →No significant difference in 90-day disability distribution on modified Rankin scale: unadjusted OR 1.01 (95% CI 0.92–1.10), P=0.84. 90-day mortality was 7.3% (lying-flat) vs 7.4% (sitting-up), OR 0.98 (0.85–1.14), P=0.8…
View trial →Primary: mRS 0-2 at 3 months achieved by 106/200 (53%) with IVT+thrombectomy vs 85/202 (42%) with IVT alone (OR 1.55, 95% CI 1.05-2.30; p=0.028; NNT=9). NIHSS at 24 h was lower with thrombectomy (median 9 vs 12; p=0.04)…
View trial →Medical management sharply reduced death/stroke vs interventional therapy: 11/109 (10.1%) vs 35/114 (30.7%); HR 0.27 (95% CI 0.14–0.54), p
View trial →Primary: survival without severe disability (mRS 0-4) at 6 mo was 38% with hemicraniectomy vs 18% control (OR 2.91, 95% CI 1.06-7.49, P=0.04). 12-mo survival: 57% (95% CI 42-72) hemicraniectomy vs 24% (95% CI 14-37) cont…
View trial →Younger age at CIS onset (OR 1.60, 95% CI 1.30–2.00, p=0.0001) and multifocal presentation (OR 1.55, 95% CI 1.10–2.19, p=0.022) predicted subsequent MS diagnosis MRI predictors: higher T2 lesion number (OR 7.46, 95% CI 1…
View trial →Time to first relapse (combination±IST): rituximab HR 5.00 (0.25–101.01) vs ravulizumab, 1.17 (0.12–10.89) vs eculizumab, 0.29 (0.04–2.23) vs satralizumab; all NS. Monotherapy network: rituximab HR 3.33 (0.13–83.16) vs r…
View trial →Relapse occurred after 39.0% (92/236) of IT discontinuations at median 5.4 months; relapsing course at discontinuation doubled hazard (HR 1.95, 95% CI 1.25-3.06, P=0.003). Longer IT reduced relapse hazard: 12-month vs 3-…
View trial →In 302 boys aged 4–
View trial →Primary: LS mean change in MG-ADL at 26 wk was −4.2 vs −2.6 (treatment difference −1.6; 95% CI −2.4 to −0.8; P
View trial →Primary: no difference in average pain (NRS) after 4 wk of active vs low-intensity sham tDCS: mean difference 0.03 (95% CI –0.40 to 0.46; p=0.89). Week-by-week during treatment, low-intensity sham actually beat active on…
View trial →TEAEs occurred in 75.0% of the placebo + booster group and 81.1% of the ABvac40 group during Part B; serious TEAEs in 5.0% vs 16.2%, with no deaths and no TEAEs leading to discontinuation No ARIA-E or aseptic meningoence…
View trial →Plasma p-tau217 (mass spectrometry) showed low diagnostic performance for detecting TRAC (
View trial →No intervention group differences in longitudinal cognitive or imaging outcomes (global Aβ, ERC tau, HC volume, WMH volume) Intervention group differences were not associated with or moderated by Aβ status or accumulatio…
View trial →No difference in PFS or OS between RT and TMZ overall IDH-mutant astrocytoma (non-codel): median OS 6.6-6.7 years, similar by arm (P=.93) IDH-mutant oligodendroglioma (1p/19q-codel): median OS 12.9 (RT) vs 14.9 (TMZ) yea…
View trial →Non-inferiority NOT met: median OS 13.0 vs 21.0 months (log-rank p
View trial →Intraoperative radiotherapy did NOT improve progression-free survival: median 11.0 vs 11.4 months (HR 1.1, 95% CI 0.85–1.44; p=0.47). Overall survival also not improved: 17.7 vs 18.7 months (HR 1.2, 95% CI 0.91–1.54; p=0…
View trial →MORGOTH achieved AUC-ROC 0.86–0.98 across 17 EEG findings and exceeded ≥20% of experts on every task; outperformed ≥90% of experts on 3 of 7 multi-expert-annotated datasets. Event-level detection was especially strong fo…
View trial →Primary endpoint (≥50% severe-seizure reduction at 12 months) was not met: 44.83% (13/29) DBS vs 26.67% (8/30) BMT, p=.14; median seizure change −44% vs −6%, p=.09. Within-group DBS seizure reduction was significant at 1…
View trial →Pooled seizure freedom achieved in 42% of patients (95% CI 27%–59%; I²=65.7%) ≥50% seizure reduction in 46% (95% CI 31%–61%; I²=84.3%) Oncologic progression in 39% (95% CI 17%–65%; I²=0%) — no signal of perampanel effect…
View trial →Higher screen exposure raised odds of migraine/headache: pooled OR 1.60 (95% CI 1.38–1.86, p
View trial →Primary — treatment discontinuation due to TEAEs across 24 weeks: 12% (33/273) atogepant vs 30% (79/267) topiramate; RR 0·4 (95% CI 0·3–0·6), p
View trial →Responder rates (≥50% reduction in monthly migraine days/attacks at weeks 9-12): rivaroxaban 78.4% (185/236), clopidogrel 66.8% (157/235), aspirin 61.7% (148/240), metoprolol 61.8% (144/233) All three antithrombotics wer…
View trial →Primary endpoint negative: MDS-UPDRS III “OFF” change at 12 mo — between-group difference 1.50 points (95% CI −4.28 to 7.28, p=1.00). Secondary — MDS-NMS total lower with FMT at 12 mo (DiD −20.3, 95% CI −35.2 to −5.4, p=…
View trial →Phase 2b, randomized 1:1, double-blind, placebo-controlled; 57 levodopa-naïve early-PD patients; bezisterim 20 mg BID vs placebo × 12 weeks. PRIMARY endpoint was PHARMACODYNAMIC (hematologic inflammatory indices — NLR, M…
View trial →